Edition:
India

Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)

2196.HK on Hong Kong Stock

23.65HKD
9:12am IST
Change (% chg)

HK$1.05 (+4.65%)
Prev Close
HK$22.60
Open
HK$22.70
Day's High
HK$23.75
Day's Low
HK$22.50
Volume
2,275,110
Avg. Vol
2,999,297
52-wk High
HK$36.05
52-wk Low
HK$19.76

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharma's Unit To Buy GlaxoSmithkline Pharmaceuticals (Suzhou)
Monday, 8 Jul 2019 

July 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT SIGNS AGREEMENT TO BUY GLAXOSMITHKLINE PHARMACEUTICALS (SUZHOU) FOR UP TO 250.0 MILLION YUAN ($36.34 million).  Full Article

Shanghai Fosun Pharmaceutical's Unit Pays 579.6 Mln Yuan For Pharma Firm Stake
Friday, 5 Jul 2019 

July 5 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT WINS BID FOR 54.8 MILLION SHARES IN PHARMA FIRM FOR 579.6 MILLION YUAN ($84.30 million).  Full Article

Shanghai Fosun Pharmaceutical Group Co Says Aohong Pharma And SDIC Gaoxin Enters Property Transaction Contract
Friday, 5 Jul 2019 

July 5 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::AOHONG PHARMA AND SDIC GAOXIN ENTERED INTO PROPERTY TRANSACTION CONTRACT.AOHONG PHARMA PROPOSED TO ACQUIRE 54.8 MILLION SHARES IN TARGET COMPANY HELD BY SDIC GAOXIN AT RMB579.633 MILLION.  Full Article

Shanghai Fosun Pharmaceutical Says CQ Pharma Enters Framework Sales And Purchases Agreement
Friday, 5 Jul 2019 

July 5 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::CQ PHARMA ENTERED AGREEMENT FOR SUPPLY OF SALES PRODUCTS AND PURCHASE OF PROCUREMENT PRODUCTS FOR A TERM OF 1 YEAR.CO AND FOSUN INTERNATIONAL ENTERED INTO MUTUAL SUPPLY FRAMEWORK AGREEMENT.UTUAL SUPPLY FRAMEWORK DEAL FOR MUTUAL SUPPLY OF PRODUCTS AND SERVICES BETWEEN GROUP AND FOSUN INTERNATIONAL FOR 1 YEAR.  Full Article

Shanghai Fosun Pharmaceutical's Unit Plans To Invest For Almost 98% Stake In Chengdu Medical Firm
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS ITS UNIT PLANS TO INVEST UP TO 746.7 MILLION YUAN ($108.55 million) IN ALMOST 98% STAKE IN CHENGDU MEDICAL FIRM.  Full Article

Shanghai Fosun Pharmaceutical's Q1 Net Profit Up 0.9 Percent Y/Y
Monday, 29 Apr 2019 

April 29 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS Q1 NET PROFIT UP 0.9 PERCENT Y/Y.  Full Article

BRIEF-Shanghai Fosun Pharmaceutical's Units Plan Project, Sign Licence Agreement With UK Firm
Tuesday, 9 Apr 2019 

Adds bullet point, link:SAYS UNIT PLANS BIO-PHARMA PROJECT WITH INVESTMENT OF UP TO 1.0 BILLION YUAN ($149.09 million).SAYS BOARD APPROVES UNIT TO SIGN LICENSE AGREEMENT WITH RENEURON LIMITED IN U.K..  Full Article

Reneuron Group Partners With Fosun Pharma In China
Tuesday, 9 Apr 2019 

April 9 (Reuters) - ReNeuron Group PLC ::RENEURON PARTNERS WITH FOSUN PHARMA IN CHINA.RENEURON TO RECEIVE UPFRONT, NEAR TERM AND ESTIMATED SUCCESS-BASED MILESTONE PAYMENTS OF £80.0 MILLION.FOSUN PHARMA WILL FULLY FUND DEVELOPMENT OF RENEURON'S CTX AND HRPC CELL THERAPY PROGRAMMES IN CHINA.RENEURON WILL ALSO RECEIVE TIERED ROYALTIES AT RATES BETWEEN 12% AND 14% ON SALES OF LICENSED PRODUCTS IN CHINESE MARKET.  Full Article

Shanghai Fosun Pharmaceutical Approved Proposed Issuance Of Corporate Bonds
Friday, 29 Mar 2019 

March 29 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::BOARD CONSIDERED AND APPROVED PROPOSED ISSUANCE OF CORPORATE BONDS.PROPOSED THAT SIZE OF PROPOSED ISSUANCE WILL NOT BE MORE THAN RMB10.0 BILLION.  Full Article

Shanghai Fosun Pharmaceutical Group Says Board Proposed Re-Election Of Executive Directors
Monday, 25 Mar 2019 

March 25 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::PROPOSED RE-ELECTION OF CHEN QIYU, YAO FANG AND WU YIFANG, AS EXECUTIVE DIRECTORS OF EIGHTH SESSION OF BOARD.BOARD PROPOSED TO APPOINT XU XIAOLIANG AND LIANG JIANFENG AS NON-EXECUTIVE DIRECTORS OF EIGHTH SESSION OF BOARD.WANG QUNBIN WILL RETIRE FROM HIS CURRENT POSITION AS A NON-EXECUTIVE DIRECTOR.ZHANG XUEQING WILL RETIRE FROM HIS CURRENT POSITION AS A NON-EXECUTIVE DIRECTOR.  Full Article